iBio IBIO Stock News

Ibio Inc (NYSEAMERICAN: IBIO) is making a run for the top in the market this morning, trading on gains of more than 18% early on. The gains come after the company announced a collaboration with the Infectious Disease Research Institute surrounding its work to bring a COVID-19 vaccine to market. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

IBIO Stock Rises On Collaboration With IDRI

In the release, iBio said that it has signed to Master Service Agreements and a Memorandum of Understanding with the Infectious Disease Research Institute or IDRI. The agreements support the company’s SARS-CoV-2 Virus Like Particle, or VLP, vaccine development.

As part of the agreement, IDRI will support pre-clinical development and provide clinical trial oversight. On the other hand, IBIO will provide process development and manufacturing services to IDRI as needed.

Moreover, as part of the MoU, the two companies will establish a separate, additional agreement within the next 60 days. This will take place if the Company opts to include one of IDRI’s novel adjuvants in the COVID-19 vaccine development program.

As a result of the new agreements, IDRI will be integrated into the collaboration between iBio and the Texas A&M University System. The company said that this creates a strong partnership that brings deep experience and advanced technologies and capabilities to the task of moving IBIO-200 into the clinic.

In a statement, Tom Isett, Co-Chairman and CEO at IBIO, had the following to offer:

We are delighted to have IDRI contribute its deep understanding of infectious diseases and vaccine development expertise to the team. We are also looking forward to evaluating the novel adjuvants in IDRI’s portfolio that may deliver even greater immunostimulatory effects. A more potent antigen-adjuvant combination would further increase our projected manufacturing capacity for production of a vaccine for COVID-19 disease.

The above statement was followed up by Corey Casper, M.D., MPH, CEO of the IDRI and Clinical Professor of Medicine and Global Health at the University of Washington. Here’s what he had to say:

We are excited to be a partner in the development of IBIO-200. Combining iBio’s VLP antigen with an IDRI adjuvant provides for promising safety and efficacy characteristics, and importantly, the ready ability to scale-up manufacturing to help meet the projected global demand for a suitable vaccine.

This News Is Huge

The news issued by iBio today is incredibly positive. We all knew that IBIO was working with Texas A&M to bring their vaccine candidate into the clinic and to the market as quickly as possible.

However, we also all know that one pencil is easy to break. However, when we add more pencils to the pile, breaking the bunch becomes more difficult. That’s essentially what’s happening today.

IBIO is a strong play already because it has the FastPharming Facility, a facility that was developed to produce vaccines in the face of a pandemic. At the same time, the company’s partnership with CC Pharming opens the door to China while offering up experience in creating vaccines for similar viruses.

Now, the company is bringing IDRI into the collaboration, adding yet another source of information, expertise, and stability to the team working to bring this vaccine to market.

All in all, following this announcement, IBIO is only getting stronger and therefore, should be on your watch list!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.